Acting Chair; Director, Advanced Education Program in Periodontology University of Alabama at Birmingham Birmingham, Alabama, United States
Disclosure(s):
Mia L. Geissinger, DDS, MS: No financial relationships to disclose
It is well-established that cigarette smoking is a significant risk factor in the development of gingivitis, periodontitis, and peri-implant diseases. While cigarette smoking rates have been declining among both adults and high school-aged children over the past 25 years, the use of e-cigarettes or vaping, as well as the state-wide legalization of cannabis has increased these methods of consumption rapidly over the last decade.
E-cigarettes are disproportionately used by young people. Given the high prevalence of e-cigarette use amongst young people and the lack of significant scientific evidence on the risks that they may pose to oral health, it is critical that dental professionals are aware of current patterns of use and the risks that tobacco products, including cigarettes and vaping products, pose to oral health.
Cannabis is the most frequently used psychotropic drug in the United States and the second-most used mind-altering substance, after alcohol. Cannabis smoking is associated with periodontal diseases, xerostomia, leukoplakia, and an increased risk of mouth and neck cancers. While cannabis use remains illegal federally, states increasingly have legalized cannabis use, and dental healthcare providers must understand the consequences of cannabis use on oral health and the implications of providing treatment to individuals who report cannabis use.
Fee: October-December: $90 January-February: $130
Learning Objectives:
Review the current scientific evidence related to the effects of tobacco, nicotine, and cannabis use on periodontal, peri-implant, and oral health.
Review the current scientific evidence related to the effects of tobacco, nicotine, and cannabis use on periodontal, peri-implant, and oral health.
Enhance counseling of patients for tobacco and cannabis cessation.